First-ever phase 3 clinical trial opens for patients with advanced anal cancer

(ECOG-ACRIN Cancer Research Group) A new clinical trial for metastatic anal cancer will determine if a drug that uses the immune system to fight cancer will prolong progression-free survival when given with standard chemotherapy. Study EA2176 will enroll 205 patients in the US with inoperable advanced (spread to other parts of the body) squamous cell anal cancer. Eligibility includes newly diagnosed patients who have not yet started treatment and patients whose cancer has returned/worsened following surgery or radiation.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news